Trial Outcomes & Findings for Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.) (NCT NCT00267774)

NCT ID: NCT00267774

Last Updated: 2017-11-13

Results Overview

All cause death, Documented myocardial infarction, Repeat revascularization (PCI and/or CABG) as adjudicated by the Clinical Event Committee

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

1005 participants

Primary outcome timeframe

1 year

Results posted on

2017-11-13

Participant Flow

Participant milestones

Participant milestones
Measure
FFR Guided PCI
Fractional flow reserve
Angio-guided PCI
Angio-guided PCI
Overall Study
STARTED
509
496
Overall Study
COMPLETED
509
496
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
FFR Guided PCI
n=509 Participants
Fractional flow reserve
Angio-guided PCI
n=496 Participants
Angio-guided PCI
Total
n=1005 Participants
Total of all reporting groups
Age, Continuous
64.6 years
STANDARD_DEVIATION 10.3 • n=5 Participants
64.2 years
STANDARD_DEVIATION 10.2 • n=7 Participants
64.4 years
STANDARD_DEVIATION 10.3 • n=5 Participants
Sex: Female, Male
Female
125 Participants
n=5 Participants
136 Participants
n=7 Participants
261 Participants
n=5 Participants
Sex: Female, Male
Male
384 Participants
n=5 Participants
360 Participants
n=7 Participants
744 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 1 year

All cause death, Documented myocardial infarction, Repeat revascularization (PCI and/or CABG) as adjudicated by the Clinical Event Committee

Outcome measures

Outcome measures
Measure
FFR Guided PCI
n=509 Participants
Fractional flow reserve
Angio-guided PCI
n=496 Participants
Angio-guided PCI
Major Adverse Cardiac Events
67 participants
91 participants

SECONDARY outcome

Timeframe: 1 year

Costs for each strategy included the initial procedural costs and costs during the 1-year follow-up. The costs of the index procedures were calculated from the actual resource consumption by determining the amount of guiding catheters, regular wires, pressure wires, balloon dilatation catheters, stents, antiplatelet therapy, adenosine, contrast media, and hospital days used for each patient's index procedure. These were multiplied by the cost of each resource in US dollars. All costs were converted to 2008 US dollars using the consumer price index (www.bls.gov).

Outcome measures

Outcome measures
Measure
FFR Guided PCI
n=509 Participants
Fractional flow reserve
Angio-guided PCI
n=496 Participants
Angio-guided PCI
Cost Effectiveness Measured as Index Procedural and Hospitalization Costs
13,182 US dollars
Standard Deviation 9667
14,878 US dollars
Standard Deviation 9509

Adverse Events

FFR Guided PCI

Serious events: 67 serious events
Other events: 0 other events
Deaths: 0 deaths

Angio-guided PCI

Serious events: 91 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
FFR Guided PCI
n=509 participants at risk
Fractional flow reserve
Angio-guided PCI
n=496 participants at risk
Angio-guided PCI
Cardiac disorders
Death
1.8%
9/509 • 1 year
Per protocol, major cardiac events were collected as adverse events.
3.0%
15/496 • 1 year
Per protocol, major cardiac events were collected as adverse events.
Cardiac disorders
Myocardial infarction
5.7%
29/509 • 1 year
Per protocol, major cardiac events were collected as adverse events.
8.7%
43/496 • 1 year
Per protocol, major cardiac events were collected as adverse events.
Cardiac disorders
Repeat vascularization
6.5%
33/509 • 1 year
Per protocol, major cardiac events were collected as adverse events.
9.5%
47/496 • 1 year
Per protocol, major cardiac events were collected as adverse events.

Other adverse events

Adverse event data not reported

Additional Information

William F. Fearon, MD

Stanford University

Phone: 650 725-2621

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place